Inify Laboratories AB

Regulatory Filings • Dec 16, 2025

Inify Laboratories - notification of trade

Inify Laboratories - notification of trade

Stockholm, Sweden, December 16, 2025; Inify Laboratories AB (publ.) has been

notified that the following transactions have been completed by a primary

insider in Inify; Fredrik Palm, CEO and primary insider in Inify, has acquired

12,000 shares in Inify at an average price of NOK 3.383 per share on December

16th. After the transaction, Palm holds 103,049 shares in the company.

This information is subject to the disclosure requirements pursuant to the EU

Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the

Norwegian Securities Trading Act.

For further information, please contact CEO, Fredrik Palm,

fredrik.palm@inify.com, or visit https://www.inify.com.

About Inify Laboratories

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in

histopathology, with a focus on streamlining patient pathways. The company

performs clinical diagnostics in prostate cancer and gastroenterology, providing

an integrated service that spans from early sample handling to final diagnosis.

The laboratory system is scalable both in handling large volumes of patient

samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to

tissue preparation and diagnosis - using a fully digital, standardised and AI

-assisted workflow. The diagnosis is always performed by a pathologist and is

assisted by Inify's proprietary AI, proven to have world-leading precision in

clinical evaluations. The entire workflow is supported by a tailor-made system

that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,

with local laboratories in Sweden and the UK. The company's share is listed on

Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103

-MERK) under the ticker

INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)